Search
Research
A population pharmacokinetic study of benzathine benzylpenicillin G administration in children and adolescents with rheumatic heart diseaseFew children and adolescents receiving BPG as secondary prophylaxis will achieve concentrations >0.02 mg/L for the majority of the time between injections
Research
Availability and administration of benzathine penicillin G for the prevention of rheumatic fever in Africa: Report of the Working Group on PenicillinBenzathine penicillin G availability should be addressed and African health workers’ knowledge and practices need to be augmented
Research
Rheumatic heart disease in Indigenous children in northern Australia: Differences in prevalence and the challenges of screeningThis study compared regional differences in the prevalence of rheumatic heart disease in Indigenous Australian children, and describes the logistical and...
Research
Supply of benzathine penicillin G: the 20-year experience in AustraliaReliable supplies of BPG are essential for delivering the recommended schedule of secondary prophylaxis for people living with RHD.
Research
Utility of auscultatory screening for detecting rheumatic heart disease in high-risk children in Australia's Northern TerritorySensitivity and positive predictive value of cardiac auscultation compared with echocardiography is poor, regardless of the expertise of the auscultator.
Research
Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart DiseaseRheumatic heart disease affects more than 40.5 million people worldwide and results in 306,000 deaths annually. Echocardiographic screening detects rheumatic heart disease at an early, latent stage. Whether secondary antibiotic prophylaxis is effective in preventing progression of latent rheumatic heart disease is unknown.
Research
Evolution, Evidence and Effect of Secondary Prophylaxis Against Rheumatic FeverThe association between group A streptococcal infection and rheumatic fever (RF) was established in the early 20th century.
Research
Changes in the clinical and epidemiological features of group A streptococcal bacteraemia in Australia's northern territoryWe aimed to measure the incidence and severity of invasive Group A Strep disease in the NT since 1996.
News & Events
$35 million to develop vaccine with potential to save half a million lives per yearA vaccine to prevent rheumatic heart disease (RHD) and other life-threatening conditions caused by the common Strep A bacteria is a step closer thanks to funding announced by Minister for Indigenous Health, Hon Ken Wyatt AM, MP, in Perth today.
Research
Surgery for rheumatic heart disease in the Northern Territory, Australia, 1997-2016: what have we gained?Between 1964 and 1996, the 10-year survival of patients having valve replacement surgery for rheumatic heart disease (RHD) in the Northern Territory, Australia, was 68%. As medical care has evolved since then, this study aimed to determine whether there has been a corresponding improvement in survival.